Analyst Price Targets — ETON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 8:11 pm | — | Canaccord Genuity | $60.00 | $37.19 | TheFly | Eton Pharmaceuticals initiated with a Buy at Canaccord |
| May 15, 2026 1:55 pm | — | H.C. Wainwright | $57.00 | $29.21 | TheFly | Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright |
| May 29, 2025 10:24 am | — | H.C. Wainwright | $35.00 | $18.92 | TheFly | Eton Pharmaceuticals price target raised to $35 from $33 at H.C. Wainwright |
| October 28, 2024 9:31 am | Chase Knickerbocker | Craig-Hallum | $15.00 | $8.44 | StreetInsider | Eton Pharmaceuticals (ETON) PT Raised to $15 at Craig-Hallum |
| October 4, 2024 6:13 am | Swayampakula Ramakanth | H.C. Wainwright | $11.00 | $6.91 | TheFly | Eton Pharmaceuticals price target raised to $11 from $9 at H.C. Wainwright |
| May 6, 2024 7:29 am | Chase Knickerbocker | Craig-Hallum | $8.00 | $3.71 | TheFly | Eton Pharmaceuticals initiated with a Buy at Craig-Hallum |
| July 25, 2022 6:25 am | — | H.C. Wainwright | $9.00 | $2.72 | Benzinga | HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Lowers Price Target to $9 |
Latest News for ETON
On May 29, 2026, Eton Pharmaceuticals Inc (ETON) shares fell 4.3% today, bringing the current price to $30.46. The stock has experienced significant volatility,
DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) from an affiliate of Knight Therapeutics, Inc…
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ETON.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.